March 1998 - Uppsala Monitoring Centre

More documents

Recommendations

Info

UMChttp://www.who-umc.org/DynPage.aspx?id=14292Page 6 of 82010-06-23Conference, Orlando (FL), USA June 7 - 11: DIA 34th Annual Meeting, Boston, USA.On May 18 - 20 UMC will have its annual planning conference which means that availabilityof staff members will be limitedMonitoring of herbal medicinesPlants have been the primary source of food and medicine for people of every culturethroughout the world. However, practitioners of traditional medicine need to be more awareof the problems of toxicity. They must learn that infrequent adverse drug reactions will notbe recognized without the existence of a formal system of reporting negative experience.Dangers of dual treatment, mixing traditional and orthodox treatments, should berecognized by both traditional and modern health practitioners. Physicians who havepatients taking any particular medicinal plant should try to document negative experiences,in order to gather enough scientific information about the adverse effects of the herb.Because adverse drug reaction reports are a critical source of herbal drug safetyinformation, the Uppsala Monitoring Centre is seeking your help in detecting and reportingany herbal adverse reactions. Your continued support is crucial in building a more completeherbal drug safety profile. The UMC is grateful to all who are reporting suspected herbaladverse reactions to a national centre.The renewed interest in the western world for plants used in traditional medicine, and therapidly growing interest in developing countries to start research programs in this areahave , unfortunately, not emphasized the great importance of taxonomic botany anddocumentation for such research. There is a need to adopt the most commonly usedbinomial names (including their binomial synonyms) for medicinal plants, to eliminate theconfusion created by the common names. Artemisia absinthium L. for example, contains anactive narcotic derivative, which can cause central nervous system disorders andgeneralized mental deterioration. This herb has at least 11 different common names(wormwood, absinthium, absinth, absinthe, madderwort, wermuth, mugwort, mingwort,warmot, magenkraut and herba absinthii), 7 of which bear no resemblance to its botanicalname. Because only common names are used, Heliotropium europaeum (heliotrope),containing pyrrolidine alkaloids, potent hepatoxins, is often confused with Valerianofficinalis (garden heliotrope), containing valepotriates, which act as a sedative and musclerelaxant in laboratory animals.Often there is uncertainty about the identity of plants reported to cause an adversereaction.The exact scientific name of the plant, the plant part used and the name of themanufacturer are very important pieces of information when writing ADR reports on herbalmedicines. Solving the existing problems requires the collaboration of botanists,phytochemists and pharmacologists.The Uppsala Monitoring Centre has established a project with the aim of attaining globalstandardization for herbal medicines. The scope is to standardize information about herbalmedicines, including their scientific names and therapeutic implications, which can varywidely between countries. The structure of the ATC-system, developed for classification oforthodox medicines, is employed in this work. The UMC group is collaborating with theUniversity of Exeter and the Royal Botanical Gardens at Kew in the UK, and with severalother international experts.In the WHO data base there are presently 8985 case reports including a herbal preparationsuspected of causing the adverse reaction. The most commonly reported reactions areDiarrhoea 121Tachycardia 62Anaphylactoid reaction 59Hepatitis 57Bronchospasm 49Convulsion 39Hallucination 39Hypertension 39Circulatory failure 37Thrombocytopenia 36
UMChttp://www.who-umc.org/DynPage.aspx?id=14292Page 7 of 82010-06-23Respiratory depression 33Mohamed FarahScientist, Herbals ProjectDramatic expansion of the WHO Drug Monitoring ProgrammeIn the previous issue of Uppsala Reports we described the new national centre in Russiaand new contacts established in India. Since then Russia has submitted adverse reactioncase reports to UMC and become an official member of the WHO Programme. At almost thesame time Peoples Republic of China submitted the first batch of reports and applied formembership in the Programme. India recently did the same, now nominating a nationalcentre. Applications for membership were recently also received from Armenia, Georgia andMacedonia although ADR reports have still not been received from these countries.The implications of these new countries entering the WHO Drug Monitoring Programme areconsiderable. Information will be received from drug markets that are different from thosenow mainly represented in the WHO data base, with different population genetics, healthcare systems, therapeutic traditions etc. adding to the value of the diversity of the WHOcollection of information. It will also mean that the WHO Drug Dictionary will be enrichedwith drug names used in these countries only. The WHO data base and information sharedwithin the WHO drug safety network will be accessible to decision makers responsible forpublic health for another 2.2 billion people.Contact information to the new national centres:Armenia China P.RDr Samvel Azatyan Prof. Zhu YonghongDepartment of Pharmacovigilance & National Centre for ADR MonitoringRational Use of Drugs National Institute for Drug ControlArmenian Drug and Medical Temple of HeavenTechnology Agency Beijing P.R.C. 10005015, Moskowian Street phone: +86-10-7017755Yerevan 375001 fax: +86-10-7013755phone: +374-2-528615 e-mail: chinaadr@public.bta.net.cnfax: +374-2-151697e-mail: pharmag@arm.r.amGeorgia IndiaDr Zaza V. Chapichadze Prof. Suresh.K. GuptaNational Centre of Pharmacovigilance Department of PharmacologyDrug and Pharmacy Department All India Institute of Medical SciencesMinistry of Health Ansari Nagar2, Gudamakari st New Delhi-110029380092 Tbilisi phone: +91-11-6864851phone: +995-32-607535 fax: +91-11-6862663fax: +995-32-605373e-mail: root@drugmonc.org.geMacedonia RussiaProf. Stojmir Petrov Prof V.K. LepakhinNational Centre for ADR Monitoring Federal Ctr for Adverse Drug Reaction Study
Page 1 and 2: UMChttp://www.who-umc.org/DynPage.a
Page 3 and 4: UMChttp://www.who-umc.org/DynPage.a
Page 5: UMChttp://www.who-umc.org/DynPage.a

March 1998 - Uppsala Monitoring Centre

Create successful ePaper yourself

Delete template?

Save as template?